Articles from the CellGene Nexus team
Perspectives on FDA regulatory strategy, cell and gene therapy, IND readiness, and translational oncology.
CellGene Nexus: Services & Client Insights
How consulting support shortens the path from discovery to clinic, how to reach the right experts, and how to judge client testimonials.
Read article →
In Vivo CAR-T in 2026: What It Means for Your IND and Regulatory
In vivo CAR-T is changing how cell therapies are made and regulated. Five questions every program should answer before IND submission.
Read article →FDA Just Opened a New Door for Individualized Gene Therapies
FDA's draft guidance introduces a plausible mechanism framework for individualized therapies in rare and ultra-rare disease.
Read article →Breaking Barriers in Oncology and Gene Therapy Consulting
The seven most common challenges in moving lab discoveries into the clinic, and how to choose the right consulting partner.
Read article →Bridging the Gap: From Lab to Patient
Why promising oncology and gene therapy programs stall before IND, and the four failure points to address early.
Read article →Have a question about your program?
Book a free discovery call and we'll point you to the right next step.
Book a Discovery Call